A Selective Approach to the Resection of Cystic Lesions of the Pancreas

Memorial Sloan-Kettering Cancer Center, USA.
Annals of Surgery (Impact Factor: 8.33). 11/2006; 244(4):572-82. DOI: 10.1097/01.sla.0000237652.84466.54
Source: PubMed


To define a group of patients with pancreatic cysts who do not require resection.
The increased use of cross-sectional imaging has resulted in an increased identification of small, asymptomatic pancreatic cysts. Data have not been available to determine which lesions should be resected.
All patients evaluated at our institution between January 1995 and January 2005 for the ICD-9 diagnosis of pancreatic cyst were reviewed. Analysis was performed to identify associations between patient and cyst characteristics, and selection of operative or nonoperative management.
Pancreatic cysts were evaluated in 539 patients. Initial management was operative in 170 patients (32%), and nonoperative (radiographic follow-up) in 369 patients (68%). Factors associated with initial operative management included presence of a solid component (45% vs. 6%, P < 0.001), larger size of the lesion (mean 4.8 cm vs. 2.4 cm, P = 0.001), and presence of symptoms (44% vs. 16%, P = 0.001). Malignancy was present in 18% (32 of 170) of patients initially resected. Mucinous tumors (n = 18) were the most common malignant histologic subtype. None of the invasive cancers arising from mucinous cysts was <3 cm. Median radiographic follow-up in patients initially managed nonoperatively was 24 months (range, 1-172 months). In 29 patients (8%), changes developed within the cyst that resulted in resection; malignancy was present in 11 of 39 (38%), representing 3% (11 of 369) of all patients being followed radiographically.
Selected patients with cystic lesions <3 cm in diameter and without a solid component may be followed radiographically with a malignancy risk (3% this study) that approximates the risk of mortality from resection. Malignancy within mucinous tumors is associated with size, and small mucinous tumors are very unlikely to be malignant.

Download full-text


Available from: Yuman Fong, Jun 02, 2015
  • Source
    • "Similarly to the mucinous cystic neoplasms and the pancreatic intraepithelial neoplasia (PanIN), IPMNs are currently considered precursors and precancerotic lesions of the pancreas [13]. The transformation from a benign into a malignant histologic type may take several years (approximately 5 years) and this event is not observed in all cases [14]. Cystic pancreatic neoplasms include a large spectrum of lesions with different radiological appearance [1, 3, 15– 18]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Intraductal papillary mucinous neoplasms (IPMNs) represent a group of cystic pancreatic neoplasms with large range of clinical behaviours, ranging from low-grade dysplasia or borderline lesions to invasive carcinomas. They can be grouped into lesions originating from the main pancreatic duct, main duct IPMNs (MD-IPMNs), and lesions which arise from secondary branches of parenchyma, denominated branch-duct IPMNs (BD-IPMNs). Management of these cystic lesions is essentially based on clinical and radiological features. The latter have been very well described in the last fifteen years, with many studies published in literature showing the main radiological features of IPMNs. Currently, the goal of imaging modalities is to identify "high-risk stigmata" or "worrisome feature" in the evaluation of pancreatic cysts. Marked dilatation of the main duct (>1 cm), large size (3-5 cm), and intramural nodules have been associated with increased risk of degeneration. BD-IPMNs could be observed as microcystic or macrocystic in appearance, with or without communication with main duct. Their imaging features are frequently overlapped with cystic neoplasms. The risk of progression for secondary IPMNs is lower, and subsequently an imaging based follow-up is very often proposed for these lesions.
    Gastroenterology Research and Practice 08/2014; 2014:765451. DOI:10.1155/2014/765451 · 1.75 Impact Factor
  • Source
    • "However, data collected after surgical resection do not reflect the characteristics of cystic lesions incidentally found in the clinical setting.2 Other investigators2,5,6 advocate selective nonoperative management arguing the improvement of cross-sectional imaging and endoscopic ultrasonography (EUS), the high morbidity associated with pancreatic surgery, and a better understanding of the natural history of certain subgroups. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The management guidelines for cystic lesions of the pancreas (CLPs) are not yet well established. This study was performed to document the long-term clinical outcome of CLPs and provide guidelines for the management and surveillance of CLPs. In this retrospective cohort study, an additional follow-up was performed in 112 patients with CLPs enrolled from 1998 to 2004 during a previous study. During follow-up for the median period of 72.3 months, the size of the CLPs increased in 18 patients (16.1%). Six of these patients experienced growth of their CLPs after 5 years of follow-up. Twenty-six patients underwent surgery during follow-up, and four malignant cysts were detected. The overall rate of malignant progression during follow-up was 3.6%. The presence of mural nodules or solid components was independently associated with the presence of malignant CLPs. Seven patients underwent surgery after 5 years of follow-up. The pathologic findings revealed malignancies in two patients. There was only one pancreas-related death during follow-up. The majority of CLPs exhibit indolent behavior and are associated with a favorable prognosis. However, long-term surveillance for more than 5 years should be performed because of the potential for growth and malignant transformation in CLPs.
    Gut and liver 10/2012; 6(4):493-500. DOI:10.5009/gnl.2012.6.4.493 · 1.81 Impact Factor
  • Source
    • "Thanks to the development of diagnostic tools, intraductal papillary mucinous neoplasm (IPMN) of the pancreas has increasingly been detected in asymptomatic patients.1-3 A branch duct IPMN smaller than 3 cm should sometimes be considered as an indication for surgical resection, even though it is associated with a lower risk of malignancy.4 Since the malignant risk of small branch duct IPMNs is uncertain, it is difficult for surgeons to determine the treatment modality, especially if the lesion is located at the head of pancreas or uncinate process. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Accurate indications and the extent of surgery for branch duct intraductal papillary mucinous neoplasm (IPMN) of the pancreas are still debatable. In particular, small tumor is located at the head portion of pancreas presents a dilemma. The purpose of this study is to compare the efficacy of enucleation (EN) with that of pancreaticoduodenectomy (PD) in patients with small (2 cm<size<3 cm) branch duct IPMN located at the head of pancreas or uncinate process. Among 155 patients who underwent pancreatic surgery due to pancreatic cystic tumors between January 2000 and December 2007 at Yonsei University Health System in Seoul, Korea, 14 patients with small (2 cm<size<3 cm) branch duct IPMN located at the head of pancreas or uncinate process were included in this study. Ten patients underwent PD, and four patients underwent EN. We compared short term surgical outcomes between the two groups. Correlation of the variables was analyzed using Mann-Whitney test and Fisher's exact test (SPSS Window 12.0). p-values less than 0.05 were considered significant. The average age was 62.21 years (±6.71 years) and consisted of 8 men and 6 women. The mean operation time and blood loss were significantly lower in EN group. There were no significant differences in other surgical morbidities. The result suggests that enucleation for small branch duct IPMN located at the head of pancreas or uncinate process is feasible and as safe as PD, despite a high rate of minor complications.
    Yonsei medical journal 01/2012; 53(1):106-10. DOI:10.3349/ymj.2012.53.1.106 · 1.29 Impact Factor
Show more